Abstract
Background: There is growing evidence that idiopathic chronic inflammatory demyelinating polyneuropathy (CIDP) and polyneuropathy in patients with diabetes mellitus (DM) that meets the electrophysiological criteria for CIDP (DM-CIDP) have many similarities. Objective: To evaluate whether DM-CIDP responds to intravenous immunoglobulin (IVIG) therapy. Patients and Methods: Twenty-six patients (mean [SD] age, 64 [8.9] years; age range, 40-80 years) with type 2 DM (n = 25), who met the electrophysiological criteria for CIDP, were given IVIG therapy (400 mg/kg body weight per day for 5 days) in a prospective open-label pilot study. All patients had quantitative evaluation using the Neuropathy Impairment Score at baseline and at the end of 4 weeks from the initiation of IVIG therapy. Results: The mean Neuropathy Impairment Score improved significantly from baseline (mean [SD], 61.5 [26.0] points) to the end of the fourth week (33 [29.6] points; P<.001). This clinically significant improvement occurred in 21 (80.8%) of the 26 patients. Conduction block occurred in 11 (42.3%) of the 26 patients; improvement in the Neuropathy Impairment Score was more frequent in patients who had a conduction block (11 of 11 patients) than in those who did not (10/15 [66.7%]; P=.03). Adverse reactions to IVIG included reversible renal dysfunction in 3 patients, flulike symptoms in 5, headache in 5, and chest pain and shortness of breath in 1. Conclusion: Although IVIG therapy seemed to improve DM-CIDP in this uncontrolled trial, a controlled trial is required for confirmation of our findings.
| Original language | English |
|---|---|
| Pages (from-to) | 751-757 |
| Number of pages | 7 |
| Journal | Archives of Neurology |
| Volume | 59 |
| Issue number | 5 |
| State | Published - May 27 2002 |
Fingerprint
ASJC Scopus subject areas
- Neuroscience(all)
Cite this
Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. / Sharma, Khema R; Cross, John; Ayyar, D. Ram; Martinez-Arizala, Alberto; Bradley, Walter G.
In: Archives of Neurology, Vol. 59, No. 5, 27.05.2002, p. 751-757.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy
AU - Sharma, Khema R
AU - Cross, John
AU - Ayyar, D. Ram
AU - Martinez-Arizala, Alberto
AU - Bradley, Walter G
PY - 2002/5/27
Y1 - 2002/5/27
N2 - Background: There is growing evidence that idiopathic chronic inflammatory demyelinating polyneuropathy (CIDP) and polyneuropathy in patients with diabetes mellitus (DM) that meets the electrophysiological criteria for CIDP (DM-CIDP) have many similarities. Objective: To evaluate whether DM-CIDP responds to intravenous immunoglobulin (IVIG) therapy. Patients and Methods: Twenty-six patients (mean [SD] age, 64 [8.9] years; age range, 40-80 years) with type 2 DM (n = 25), who met the electrophysiological criteria for CIDP, were given IVIG therapy (400 mg/kg body weight per day for 5 days) in a prospective open-label pilot study. All patients had quantitative evaluation using the Neuropathy Impairment Score at baseline and at the end of 4 weeks from the initiation of IVIG therapy. Results: The mean Neuropathy Impairment Score improved significantly from baseline (mean [SD], 61.5 [26.0] points) to the end of the fourth week (33 [29.6] points; P<.001). This clinically significant improvement occurred in 21 (80.8%) of the 26 patients. Conduction block occurred in 11 (42.3%) of the 26 patients; improvement in the Neuropathy Impairment Score was more frequent in patients who had a conduction block (11 of 11 patients) than in those who did not (10/15 [66.7%]; P=.03). Adverse reactions to IVIG included reversible renal dysfunction in 3 patients, flulike symptoms in 5, headache in 5, and chest pain and shortness of breath in 1. Conclusion: Although IVIG therapy seemed to improve DM-CIDP in this uncontrolled trial, a controlled trial is required for confirmation of our findings.
AB - Background: There is growing evidence that idiopathic chronic inflammatory demyelinating polyneuropathy (CIDP) and polyneuropathy in patients with diabetes mellitus (DM) that meets the electrophysiological criteria for CIDP (DM-CIDP) have many similarities. Objective: To evaluate whether DM-CIDP responds to intravenous immunoglobulin (IVIG) therapy. Patients and Methods: Twenty-six patients (mean [SD] age, 64 [8.9] years; age range, 40-80 years) with type 2 DM (n = 25), who met the electrophysiological criteria for CIDP, were given IVIG therapy (400 mg/kg body weight per day for 5 days) in a prospective open-label pilot study. All patients had quantitative evaluation using the Neuropathy Impairment Score at baseline and at the end of 4 weeks from the initiation of IVIG therapy. Results: The mean Neuropathy Impairment Score improved significantly from baseline (mean [SD], 61.5 [26.0] points) to the end of the fourth week (33 [29.6] points; P<.001). This clinically significant improvement occurred in 21 (80.8%) of the 26 patients. Conduction block occurred in 11 (42.3%) of the 26 patients; improvement in the Neuropathy Impairment Score was more frequent in patients who had a conduction block (11 of 11 patients) than in those who did not (10/15 [66.7%]; P=.03). Adverse reactions to IVIG included reversible renal dysfunction in 3 patients, flulike symptoms in 5, headache in 5, and chest pain and shortness of breath in 1. Conclusion: Although IVIG therapy seemed to improve DM-CIDP in this uncontrolled trial, a controlled trial is required for confirmation of our findings.
UR - http://www.scopus.com/inward/record.url?scp=0036091494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036091494&partnerID=8YFLogxK
M3 - Article
VL - 59
SP - 751
EP - 757
JO - Archives of Neurology
JF - Archives of Neurology
SN - 0003-9942
IS - 5
ER -